Loading
AUGMENT showed that pairing rituximab with the immune-modulating tablet lenalidomide kept relapsed follicular lymphoma under control for much longer than rituximab alone, giving patients a chemotherapy-free option.
AUGMENT randomised 358 patients with relapsed or refractory follicular lymphoma (grades 1 to 3a) or marginal zone lymphoma who were not rituximab-refractory to rituximab plus lenalidomide for 12 cycles or rituximab plus placebo. The primary endpoint was progression-free survival by independent review.
The lenalidomide combination roughly tripled median progression-free survival compared with rituximab alone and improved response rates, at the cost of more neutropenia and skin reactions. It was approved in the United States in May 2019 for previously treated follicular and marginal zone lymphoma and became the reference chemotherapy-free regimen against which bispecific antibodies are now being tested.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
358 enrolled.
Shares POD24: progression of follicular lymphoma within two years, and why it changes the plan, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma, Follicular lymphoma and the tag subtype-trials.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation) and the tag subtype-trials.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation) and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.
Shares Lenalidomide and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.